129 related articles for article (PubMed ID: 36038497)
1. Role of therapeutic inertia in glycemic control according to individualized objectives in a cohort of patients with type 2 diabetes. Results from CONCARDIA2.
Hidalgo Rodríguez A; Martín Enguix D; Aguirre Rodríguez JC; Sánchez Cambronero M
Endocrinol Diabetes Nutr (Engl Ed); 2022; 69(7):458-465. PubMed ID: 36038497
[TBL] [Abstract][Full Text] [Related]
2. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
Rajpathak SN; Rajgopalan S; Engel SS
J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
[TBL] [Abstract][Full Text] [Related]
3. Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States.
Fernandes G; Sawhney B; Hannachi H; Liu J; Wang T; Fu AZ; Iglay K; McNeill A; Rajpathak S
Curr Med Res Opin; 2020 May; 36(5):741-748. PubMed ID: 31990206
[No Abstract] [Full Text] [Related]
4. Patient and Provider Factors Affecting Clinical Inertia in Patients With Type 2 Diabetes on Metformin Monotherapy.
Mahabaleshwarkar R; Gohs F; Mulder H; Wilkins N; DeSantis A; Anderson WE; Ejzykowicz F; Rajpathak S; Norton HJ
Clin Ther; 2017 Aug; 39(8):1658-1670.e6. PubMed ID: 28689692
[TBL] [Abstract][Full Text] [Related]
5. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Fu AZ; Sheehan JJ
Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
[TBL] [Abstract][Full Text] [Related]
6. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
[TBL] [Abstract][Full Text] [Related]
7. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
9. Is insulin the preferred treatment for HbA1c >9%?
Bloomgarden Z
J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
[TBL] [Abstract][Full Text] [Related]
10. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
11. Early Glycemic Control and Magnitude of HbA
Svensson E; Baggesen LM; Johnsen SP; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Thomsen RW
Diabetes Care; 2017 Jun; 40(6):800-807. PubMed ID: 28404659
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
[TBL] [Abstract][Full Text] [Related]
13. Slow response to loss of glycemic control in type 2 diabetes mellitus.
Brown JB; Nichols GA
Am J Manag Care; 2003 Mar; 9(3):213-7. PubMed ID: 12643338
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
[TBL] [Abstract][Full Text] [Related]
15. Insulin Inertia Among People With Type 2 Diabetes Mellitus in Qatar: The INERT-Q Study.
Bashir M; Thani NA; Khalid A; Khalil O; Alamer Z; Hamad MK; Karuppasamy G; Abufaeid M; Elbidairi M; Al-Mohnnadi D; Elhadd T; Zirie M
Endocrinol Diabetes Metab; 2024 Jul; 7(4):e00495. PubMed ID: 38844642
[TBL] [Abstract][Full Text] [Related]
16. Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care.
Mata-Cases M; Benito-Badorrey B; Roura-Olmeda P; Franch-Nadal J; Pepió-Vilaubí JM; Saez M; Coll-de-Tuero G;
Curr Med Res Opin; 2013 Nov; 29(11):1495-502. PubMed ID: 23944631
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents.
Ampudia-Blasco FJ; Palanca A; Trillo JL; Navarro J; Real JT
J Diabetes Complications; 2021 Mar; 35(3):107828. PubMed ID: 33436143
[TBL] [Abstract][Full Text] [Related]
18. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
Jiang G; Luk AO; Tam CHT; Lau ES; Ozaki R; Chow EYK; Kong APS; Lim CKP; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JYY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung SKS; Cheng YL; Chow CC; Pearson ER; So WY; Chan JCN; Ma RCW; ;
PLoS Med; 2020 Jul; 17(7):e1003209. PubMed ID: 32722720
[TBL] [Abstract][Full Text] [Related]
19. Unmasking Fracture Risk in Type 2 Diabetes: The Association of Longitudinal Glycemic Hemoglobin Level and Medications.
Wang B; Wang Z; Poundarik AA; Zaki MJ; Bockman RS; Glicksberg BS; Nadkarni GN; Vashishth D
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1390-e1401. PubMed ID: 34888676
[TBL] [Abstract][Full Text] [Related]
20. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Dailey GE; Mohideen P; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
